Date: 2016-04-18
Type of information: R&D agreement
Compound: antibody therapeutics targeting G protein-coupled receptors (GPCR)
Company: Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) Kymab (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: monoclonal antibody
Disease:
Details: * On April 18, 2016, Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group and Kymab, a leading human monoclonal antibody biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel antibody therapeutics targeting a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology. Under the agreement, Heptares will apply its StaR® platform to create stable antigens based on multiple GPCR targets chosen by the companies. Kymab will then use its Kymouse™ human antibody discovery platform to generate antibodies in response to immunisation with these antigens. The Kymouse platform will assure the highest probability of finding the best-in-class antibodies with highly attractive drug properties. Promising leads will be progressed using the partners’ complementary skills, resources and development capabilities in order to bring innovative products into the clinic.
Financial terms: Under the agreement, the companies will jointly conduct and share the costs of each antibody discovery and development programme.
Latest news:
